Difference between revisions of "Eberhart 2009 Leukemia"
Beno Marija (talk | contribs) |
Beno Marija (talk | contribs) |
||
Line 16: | Line 16: | ||
|tissues=Blood cells, Lymphocyte | |tissues=Blood cells, Lymphocyte | ||
|preparations=Intact cells | |preparations=Intact cells | ||
|couplingstates=LEAK, ROUTINE, | |couplingstates=LEAK, ROUTINE, ET | ||
|pathways=ROX | |pathways=ROX | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
}} | }} |
Revision as of 17:54, 9 November 2017
Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis. Leukemia 23:2167-70. |
Β» PMID: 19657369; Open Access
Eberhart K, Renner K, Ritter I, Kastenberger M, Singer K, Hellerbrand C, Kreutz M, Kofler R, Oefner PJ (2009) Leukemia
Abstract: Glucocorticoids (GCs) are an essential component of most chemotherapy protocols for lymphoid malignancies, particularly childhood acute lymphoblastic leukemia (ALL).1, 2 Nevertheless, adverse side effects of GCs call for improved therapy protocols.
GCs decrease the activity of glycolytic enzymes3 and upregulate the expression of the glycolytic regulator, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in vitro and in vivo.4 This led us to investigate whether co-administration of 2-deoxy-glucose (2-DG), an inhibitor of glycolysis, systemic application of which up to a blood concentration of approximately 3 mM had caused a transient hyperglycemia only,5 might potentiate the apoptotic effect of GC.
β’ O2k-Network Lab: DE Regensburg Renner-Sattler K, DE Regensburg Oefner PJ
Labels: MiParea: Respiration
Pathology: Cancer
Organism: Human Tissue;cell: Blood cells, Lymphocyte Preparation: Intact cells
Coupling state: LEAK, ROUTINE, ET
Pathway: ROX
HRR: Oxygraph-2k